Interaction of low molecular weight hyaluronan with CD44 and toll-like receptors promotes the actin filament-associated protein 110-actin binding and MyD88-NFκB signaling leading to proinflammatory cytokine/chemokine production and breast tumor invasion

Cytoskeleton

Volumn 68, Issue 12, 2011, Pages 671-693

  Bourguignon, Lilly Y W ^a   Wong, Gabriel ^a   Earle, Christine A ^a   Xia, Weiliang ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Actin binding protein; Breast cancer; CD44; Hyaluronan; Toll like receptors

Indexed keywords

ACTIN BINDING PROTEIN; CD44V ANTIGEN; CHEMOKINE; HEAT SHOCK PROTEIN 110; HYALURONIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 8; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR;

ACTIN FILAMENT; ARTICLE; BREAST TUMOR; CELL INVASION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; GENE TARGETING; HUMAN; HUMAN CELL; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; TUMOR CELL;

ANIMALS; ANTIGENS, CD44; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CHEMOKINES; CYTOKINES; FEMALE; HUMANS; HYALURONIC ACID; MICROFILAMENT PROTEINS; NF-KAPPA B; PHOSPHOPROTEINS; RATS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 83555176258     PISSN: 19493584     EISSN: 19493592     Source Type: Journal    
DOI: 10.1002/cm.20544     Document Type: Article

References (79)

1. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. 2003. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100: 3983-3988.
2. Auvinen P, Tammi R, Tammi M, Johansson R, Kosma VM. 2005. Expression of CD44s, CD44v3 and CD 44v6 in benign and malignant breast lesions: correlation and colocalization with hyaluronan. Histopathology 47: 420-428.
3. Banerji S, Wright AJ, Noble M, Mahoney DJ, Campbell ID, Day AJ, Jackson DG. 2007. Structures of the Cd44-hyaluronan complex provide insight into a fundamental carbohydrate-protein interaction. Nat Struct Mol Biol 14: 234-239.
4. Bauer S, Muller T, Hamm S. 2009. Pattern recognition by toll-like receptors. Adv Exp Med Biol 653: 15-34.
5. Ben-Baruch A. 2003. Host microenvironment in breast cancer development: inflammatory cells, cytokines and chemokines in breast cancer progression: reciprocal tumor-microenvironment interactions. Breast Cancer Res 5: 31-36.
6. Bourguignon LY. 2001. CD44-mediated oncogenic signaling and cytoskeleton activation during mammary tumor progression. J Mammary Gland Biol Neoplasia 6: 287-297.
7. Bourguignon LY. 2008. Hyaluronan-mediated CD44 activation of RhoGTPase signaling and cytoskeleton function promotes tumor progression. Semin Cancer Biol 18: 251-259.
8. Bourguignon LY. 2009. Hyaluronan-mediated CD44 interaction with receptor and non-receptor kinases promotes oncogenic signaling, cytoskeleton activation and tumor progression. In: Stern R, editor. Hyaluronan in Cancer Biology. Waltham, MA: Elsevier Publication Co., pp 89-107.
9. Bourguignon LY, Gilad E, Brightman A, Diedrich F, Singleton P. 2006. Hyaluronan-CD44 interaction with leukemia-associated RhoGEF and epidermal growth factor receptor promotes Rho/Ras co-activation, phospholipase C epsilon-Ca2+ signaling, and cytoskeleton modification in head and neck squamous cell carcinoma cells. J Biol Chem 281: 14026-14040.
10. Bourguignon LY, Gilad E, Rothman K, Peyrollier K. 2005. Hyaluronan-CD44 interaction with IQGAP1 promotes Cdc42 and ERK signaling, leading to actin binding, Elk-1/estrogen receptor transcriptional activation, and ovarian cancer progression. J Biol Chem 280: 11961-11972.
11. Bourguignon LY, Peyrollier K, Gilad E, Brightman A. 2007. Hyaluronan-CD44 interaction with neural Wiskott-Aldrich syndrome protein (N-WASP) promotes actin polymerization and ErbB2 activation leading to beta-catenin nuclear translocation, transcriptional up-regulation, and cell migration in ovarian tumor cells. J Biol Chem 282: 1265-1280.
12. Bourguignon LY, Peyrollier K, Xia W, Gilad E. 2008. Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells. J Biol Chem 283: 17635-17651.
13. Bourguignon LY, Singleton PA, Diedrich F. 2004a. Hyaluronan-CD44 interaction with Rac1-dependent protein kinase N-gamma promotes phospholipase Cgamma1 activation, Ca(2+) signaling, and cortactin-cytoskeleton function leading to keratinocyte adhesion and differentiation. J Biol Chem 279: 29654-29669.
14. Bourguignon LY, Singleton PA, Diedrich F, Stern R, Gilad E. 2004b. CD44 interaction with Na+-H+ exchanger (NHE1) creates acidic microenvironments leading to hyaluronidase-2 and cathepsin B activation and breast tumor cell invasion. J Biol Chem 279: 26991-27007.
15. Bourguignon LY, Singleton PA, Zhu H, Diedrich F. 2003. Hyaluronan-mediated CD44 interaction with RhoGEF and Rho kinase promotes Grb2-associated binder-1 phosphorylation and phosphatidylinositol 3-kinase signaling leading to cytokine (macrophage-colony stimulating factor) production and breast tumor progression. J Biol Chem 278: 29420-29434.
16. Bourguignon LY, Singleton PA, Zhu H, Zhou B. 2002. Hyaluronan promotes signaling interaction between CD44 and the transforming growth factor beta receptor I in metastatic breast tumor cells. J Biol Chem 277: 39703-39712.
17. Bourguignon LY, Spevak CC, Wong G, Xia W, Gilad E. 2009a. Hyaluronan-CD44 interaction with protein kinase C(epsilon) promotes oncogenic signaling by the stem cell marker Nanog and the production of microRNA-21, leading to down-regulation of the tumor suppressor protein PDCD4, anti-apoptosis, and chemotherapy resistance in breast tumor cells. J Biol Chem 284: 26533-26546.
18. Bourguignon LY, Xia W, Wong G. 2009b. Hyaluronan-mediated CD44 interaction with p300 and SIRT1 regulates beta-catenin signaling and NFkappaB-specific transcription activity leading to MDR1 and Bcl-xL gene expression and chemoresistance in breast tumor cells. J Biol Chem 284: 2657-2671.
19. Bourguignon LY, Zhu H, Chu A, Iida N, Zhang L, Hung MC. 1997. Interaction between the adhesion receptor, CD44, and the oncogene product, p185HER2, promotes human ovarian tumor cell activation. J Biol Chem 272: 27913-27918.
20. Bourguignon LY, Zhu H, Shao L, Chen YW. 2001a. CD44 interaction with c-Src kinase promotes cortactin-mediated cytoskeleton function and hyaluronic acid-dependent ovarian tumor cell migration. J Biol Chem 276: 7327-7336.
21. Bourguignon LY, Zhu H, Zhou B, Diedrich F, Singleton PA, Hung MC. 2001b. Hyaluronan promotes CD44v3-Vav2 interaction with Grb2-p185(HER2) and induces Rac1 and Ras signaling during ovarian tumor cell migration and growth. J Biol Chem 276: 48679-48692.
22. Bourguignon LY, Zhu H, Shao L, Zhu D, Chen YW. 1999. Rho-kinase (ROK) promotes CD44v(3, 8-10)-ankyrin interaction and tumor cell migration in metastatic breast cancer cells. Cell Motil Cytoskeleton 43: 269-287.
23. Bretscher A, Edwards K, Fehon RG. 2002. ERM proteins and merlin: integrators at the cell cortex. Nat Rev Mol Cell Biol 3: 586-599.
24. Calogero RA, Cordero F, Forni G, Cavallo F. 2007. Inflammation and breast cancer. Inflammatory component of mammary carcinogenesis in ErbB2 transgenic mice. Breast Cancer Res 9: 211-219.
25. Cuff CA, Kothapalli D, Azonobi I, Chun S, Zhang Y, Belkin R, Yeh C, Secreto A, Assoian RK, Rader DJ. 2001. The adhesion receptor CD44 promotes atherosclerosis by mediating inflammatory cell recruitment and vascular cell activation. J Clin Invest 108: 1031-1040.
26. De Larco JE, Wuertz BR, Rosner KA, Erickson SA, Gamache DE, Manivel JC, Furcht LT. 2001. A potential role for interleukin-8 in the metastatic phenotype of breast carcinoma cells. Am J Pathol 158: 639-646.
27. Delpech B, Chevallier B, Reinhardt N, Julien JP, Duval C, Maingonnat C, Bastit P, Asselain B. 1990. Serum hyaluronan (hyaluronic acid) in breast cancer patients. Int J Cancer 46: 388-390.
28. Dorfleutner A, Stehlik C, Zhang J, Gallick GE, Flynn DC. 2007. AFAP-110 is required for actin stress fiber formation and cell adhesion in MDA-MB-231 breast cancer cells. J Cell Physiol 213: 740-749.
29. Flynn DC, Leu TH, Reynolds AB, Parsons JT. 1993. Identification and sequence analysis of cDNAs encoding a 110-kilodalton actin filament-associated pp60src substrate. Mol Cell Biol 13: 7892-7900.
30. Frasor J, Weaver AE, Pradhan M, Mehta K. 2008. Synergistic up-regulation of prostaglandin E synthase expression in breast cancer cells by 17beta-estradiol and proinflammatory cytokines. Endocrinology 149: 6272-6279.
31. Green AR, Green VL, White MC, Speirs V. 1997. Expression of cytokine messenger RNA in normal and neoplastic human breast tissue: identification of interleukin-8 as a potential regulatory factor in breast tumours. Int J Cancer 72: 937-941.
32. Guappone AC, Flynn DC. 1997. The integrity of the SH3 binding motif of AFAP-110 is required to facilitate tyrosine phosphorylation by, and stable complex formation with, Src. Mol Cell Biochem 175: 243-252.
33. Guappone AC, Weimer T, Flynn DC. 1998. Formation of a stable src-AFAP-110 complex through either an amino-terminal or a carboxy-terminal SH2-binding motif. Mol Carcinog 22: 110-119.
34. Haylock DN, Nilsson SK. 2006. The role of hyaluronic acid in hemopoietic stem cell biology. Regen Med 1: 437-445.
35. Iida N, Bourguignon LY. 1995. New CD44 splice variants associated with human breast cancers. J Cell Physiol 162: 127-133.
36. Iida N, Bourguignon LY. 1997. Coexpression of CD44 variant (v10/ex14) and CD44S in human mammary epithelial cells promotes tumorigenesis. J Cell Physiol 171: 152-160.
37. Itano N, Kimata K. 1996. Expression cloning and molecular characterization of HAS protein, a eukaryotic hyaluronan synthase. J Biol Chem 271: 9875-9878.
38. Jiang D, Liang J, Fan J, Yu S, Chen S, Luo Y, Prestwich GD, Mascarenhas MM, Garg HG, Quinn DA, Homer RJ, Goldstein DR, Bucala R, Lee PJ, Medzhitov R, Noble PW. 2005. Regulation of lung injury and repair by toll-like receptors and hyaluronan. Nat Med 11: 1173-1179.
39. Kelly MG, Alvero AB, Chen R, Silasi DA, Abrahams VM, Chan S, Visintin I, Rutherford T, Mor G. 2006. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res 66: 3859-3868.
40. Kothapalli D, Zhao L, Hawthorne EA, Cheng Y, Lee E, Pure E, Assoian RK. 2007. Hyaluronan and CD44 antagonize mitogen-dependent cyclin D1 expression in mesenchymal cells. J Cell Biol 176: 535-544.
41. Kothapalli D, Floers J, Xu T, Pure E, Assoian RK. 2008. Differential activation of ERK and Rac mediates the proliferative and anti-proliferative effects of hyaluronan and Cd44. J Biol Chem 283: 31823-31829.
42. Lesley J, Hascall VC, Tammi M, Hyman R. 2000. Hyaluronan binding by cell surface CD44. J Biol Chem 275: 26967-26975.
43. Lokeshwar VB, Iida N, Bourguignon LY. 1996. The cell adhesion molecule, GP116, is a new CD44 variant (ex14/v10) involved in hyaluronic acid binding and endothelial cell proliferation. J Biol Chem 271: 23853-23864.
44. Matou-Nasri S, Gaffney J, Kumar S, Slevin M. 2009. Oligosaccharides of hyaluronan induce angiogenesis through distinct CD44 and RHAMM-mediated signalling pathways involving Cdc2 and gamma-adducin. Int J Oncol 35: 761-773.
45. Medzhitov R, Preston-Hurlburt P, Janeway CA, Jr. 1997. A human homologue of the drosophila Toll protein signals activation of adaptive immunity. Nature 388: 394-397.
46. Miller LJ, Kurtzman SH, Wang Y, Anderson KH, Lindquist RR, Kreutzer DL. 1998. Expression of interleukin-8 receptors on tumor cells and vascular endothelial cells in human breast cancer tissue. Anticancer Res 18: 77-81.
47. Molteni M, Marabella D, Orlandi C, Rossetti C. 2006. Melanoma cell lines are responsive in vitro to lipopolysaccharide and express TLR-4. Cancer Lett 235: 75-83.
48. Nicolini A, Carpi A, Rossi G. 2006. Cytokines in breast cancer. Cytokine Growth Factor Rev 17: 325-337.
49. Noble PW. 2002. Hyaluronan and its catabolic products in tissue injury and repair. Matrix Biol 21: 25-29.
50. Pantschenko AG, Pushkar I, Anderson KH, Wang Y, Miller LJ, Kurtzman SH, Barrows G, Kreutzer DL. 2003. The interleukin-1 family of cytokines and receptors in human breast cancer: implications for tumor progression. Int J Oncol 23: 269-284.
51. Premkumar VG, Yuvaraj S, Vijayasarathy K, Gangadaran SG, Sachdanandam P. 2007. Serum cytokine levels of interleukin-1beta, -6, -8, tumour necrosis factor-alpha and vascular endothelial growth factor in breast cancer patients treated with tamoxifen and supplemented with co-enzyme Q(10), riboflavin and niacin. Basic Clin Pharmacol Toxicol 100: 387-391.
52. Qian Y, Baisden JM, Westin EH, Guappone AC, Koay TC, Flynn DC. 1998. Src can regulate carboxy terminal interactions with AFAP-110, which influence self-association, cell localization and actin filament integrity. Oncogene 16: 2185-2195.
53. Qian Y, Baisden JM, Zot HG, Van Winkle WB, Flynn DC. 2000. The carboxy terminus of AFAP-110 modulates direct interactions with actin filaments and regulates its ability to alter actin filament integrity and induce lamellipodia formation. Exp Cell Res 255: 102-113.
54. Qian Y, Gatesman AS, Baisden JM, Zot HG, Cherezova L, Qazi I, Mazloum N, Lee MY, Guappone-Koay A, Flynn DC. 2004. Analysis of the role of the leucine zipper motif in regulating the ability of AFAP-110 to alter actin filament integrity. J Cell Biochem 91: 602-620.
55. Radisky ES, Radisky DC. 2007. Stromal induction of breast cancer: inflammation and invasion. Rev Endocr Metab Disord 8: 279-287.
56. Scheibner KA, Lutz MA, Boodoo S, Fenton MJ, Powell JD, Horton MR. 2006. Hyaluronan fragments act as an endogenous danger signal by engaging TLR2. J Immunol 177: 1272-1281.
57. Schmitz F, Mages J, Heit A, Lang R, Wagner H. 2004. Transcriptional activation induced in macrophages by toll-like receptor (TLR) ligands: from expression profiling to a model of TLR signaling. Eur J Immunol 34: 2863-2873.
58. Singleton PA, Bourguignon LY. 2002. CD44v10 interaction with Rho-kinase (ROK) activates inositol 1, 4, 5-triphosphate (IP3) receptor-mediated Ca2+ signaling during hyaluronan (HA)-induced endothelial cell migration. Cell Motil Cytoskeleton 53: 293-316.
59. Singleton PA, Bourguignon LY. 2004. CD44 interaction with ankyrin and IP3 receptor in lipid rafts promotes hyaluronan-mediated Ca2+ signaling leading to nitric oxide production and endothelial cell adhesion and proliferation. Exp Cell Res 295: 102-118.
60. Slomiany MG, Dai L, Bomar PA, Knackstedt TJ, Kranc DA, Tolliver L, Maria BL, Toole BP. 2009a. Abrogating drug resistance in malignant peripheral nerve sheath tumors by disrupting hyaluronan-CD44 interactions with small hyaluronan oligosaccharides. Cancer Res 69: 4992-4998.
61. Slomiany MG, Dai L, Tolliver LB, Grass GD, Zeng Y, Toole BP. 2009b. Inhibition of functional hyaluronan-CD44 interactions in CD133-positive primary human ovarian carcinoma cells by small hyaluronan oligosaccharides. Clin Cancer Res 15: 7593-7601.
62. Smith HS, Stern R, Liu E, Benz C. 1991. Early and late events in the development of human breast cancer. Basic Life Sci 57: 329-337.
63. Snoussi K, Strosberg AD, Bouaouina N, Ben Ahmed S, Chouchane L. 2005. Genetic variation in pro-inflammatory cytokines (interleukin-1beta, interleukin-1alpha and interleukin-6) associated with the aggressive forms, survival, and relapse prediction of breast carcinoma. Eur Cytokine Netw 16: 253-260.
64. Snyder BN, Cho Y, Qian Y, Coad JE, Flynn DC, Cunnick JM. 2011. FAP1L1 is a novel adaptor protein of the AFAP family that interacts with cortactin and localizes to invadosomes. Eur J Cell Biol 90: 376-389.
65. Spicer AP, Nguyen TK. 1999. Mammalian hyaluronan synthases: investigation of functional relationships in vivo. Biochem Soc Trans 27: 109-115.
66. Stern R, Jedrzejas MJ. 2006. Hyaluronidases: their genomics, structures, and mechanisms of action. Chem Rev 106: 818-839.
67. Takeda K, Kaisho T, Akira S. 2003. Toll-like receptors. Annu Rev Immunol 21: 335-376.
68. Toole BP, Slomiany MG. 2008. Hyaluronan: a constitutive regulator of chemoresistance and malignancy in cancer cells. Semin Cancer Biol 18: 244-250.
69. Toole BP, Wight TN, Tammi MI. 2002. Hyaluronan-cell interactions in cancer and vascular disease. J Biol Chem 277: 4593-4596.
70. Toubi E, Shoenfeld Y. 2004. Toll-like receptors and their role in the development of autoimmune diseases. Autoimmunity 37: 183-188.
71. Tsuji S, Matsumoto M, Takeuchi O, Akira S, Azuma I, Hayashi A, Toyoshima K, Seya T. 2000. Maturation of human dendritic cells by cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guerin: involvement of Toll-like receptors. Infect Immun 68: 6883-6890.
72. Turley EA, Noble PW, Bourguignon LY. 2002. Signaling properties of hyaluronan receptors. J Biol Chem 277: 4589-4592.
73. Uehori J, Matsumoto M, Tsuji S, Akazawa T, Takeuchi O, Akira S, Kawata T, Azuma I, Toyoshima K, Seya T. 2003. Simultaneous blocking of human Toll-like receptors 2 and 4 suppresses myeloid dendritic cell activation induced by Mycobacterium bovis bacillus Calmette-Guerin peptidoglycan. Infect Immun 71: 4238-4249.
74. Wang SJ, Bourguignon LY. 2006a. Hyaluronan-CD44 promotes phospholipase C-mediated Ca2 signaling and cisplatin resistance in head and neck cancer. Arch Otolaryngol Head Neck Surg 132: 19-24.
75. Wang SJ, Bourguignon LY. 2006b. Hyaluronan and the interaction between CD44 and epidermal growth factor receptor in oncogenic signaling and chemotherapy resistance in head and neck cancer. Arch Otolaryngol Head Neck Surg 132: 771-778.
76. Weigel PH, Hascall VC, Tammi M. 1997. Hyaluronan synthases. J Biol Chem 272: 13997-14000.
77. Woodward WA, Buchholz TA. 2008. The role of locoregional therapy in inflammatory breast cancer. Semin Oncol 35: 78-86.
78. Xie W, Wang Y, Huang Y, Yang H, Wang J, Hu Z. 2009. Toll-like receptor 2 mediates invasion via activating NF-kappaB in MDA-MB-231 breast cancer cells. Biochem Biophys Res Commun 379: 1027-1032.
79. Yamauchi H, Cristofanilli M, Nakamura S, Hortobagyi GN, Ueno NT. 2009. Molecular targets for treatment of inflammatory breast cancer. Nat Rev Clin Oncol 6: 387-394.